



Atty. Dkt. No.	M#	Client Ref.
	037003-0276603	1995-30-0233D2

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Applicant:	ANDERSON et al.		
Appln. No.:	09/758,173		
Filing Date:	January 12, 2001		
Examiner:	Gambel, P.	Group Art Unit:	1644

Date: May 6, 2004 Page 1 of 3

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
BO	AR 4,816,397	03/1989	Boss	435	68	
	BR 4,816,567	03/1989	Cabilly	530	387	
	CR 5,116,964	05/1992	Capon	536	27	
	DR 5,885,579	03/1999	Linsley			
	ER 6,162,432	12/2000	Wallner			

FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
					Enclosed	No	Enclose	No
	FR 0 171 496 B1	05/1993	EP	Taniguchi				
	GR 0 173 494 A2	03/1986	EP	Morrison				
	HR 0 239 400 B1	08/1994	EP	Winter				
	IR 0 194 276 B1	08/1993	EP	Neuberger				
	JR 0 451 216 B1	10/1991	EP	Queen				
	KR 0 555 880 A2, A3	08/1993	EP	Aruffo				
	LR 0 682 040 A1	11/1995	EP	Queen				
	MR 2 177 096 A	03/1986	GB	Neuberger				
	NR WO 92/06193	04/1992	WO	Gorman				
	OR WO 93/09812	05/1993	WO	Lederman				
	PR WO 94/28912	12/1994	WO	Thompson				
	QR WO 95/06481	03/1995	WO	Noelle				
	RR WO 95/06666	03/1995	WO	Noelle				
	SR WO 98/19706	05/1998	WO	Anderson				



OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

TR	Armitage, R.J., et al., Molecular and biological characterization of a murine ligand for CD40, Nature, 1992, 357:80-82.
UR	Asuma, M. et al., Functional Expression of B7/BB1 on Activated T Lymphocytes, J. Exp. Med., 1992, 177:845-850.
VR	Ben-Nun, A. et al., The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis, Eur J. Immunol., 1981, 11:195-199.
WR	Blazar, B.R. et al., Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells, J Immunol., 1996, 157:3250-3259.
XR	Capon, D.J., et al., Designing CD4 immunoadhesins for AIDS therapy, Nature, 1989, 337, 525-531.
YR	Dautigny, A., et al., Molecular cloning and nucleotide sequence of a cDNA clone coding for rat brain myelin proteolipid, FEBS Lett., 1985, 188(1):33-36.
ZR	Durie, F.H., et al., The role of CD40 and its ligand (gp39) in peripheral and central tolerance and its contribution to autoimmune disease, Research in Immunology, 1994, 145(3), 200-205 & 244-249.
AAR	Durie, F.H., et al., Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40, Science, 1993, 261:1328-1330.

Philip Gambel
6/18/04

BBR	Freeman, G.J. et al., Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice, Science, 1993, 262:907-909.
CCR	Freeman, G.J. et al., B7, A new member of the Ig Superfamily with unique expression on activated and neoplastic B cells, J of Immunol., 1989, 143:2714-2722.
DDR	Freeman, G.J. et al., Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation, Science, 1993, 262:909-911.
EBR	Gerritse, K., et al., CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis, Proc. Natl. Acad. Sci. USA, 1996, 93:2499-2504.
FFR	Gottlieb, A. et al., Results of a single-dose, dose-escalating trial of an anti-B7.1 monoclonal antibody (IDEC-114) in patients with psoriasis, J Invest Dermatol., 2000, 114:840, Abstract No. 546.
GGR	Gottlieb, A. et al., Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody, J Am Acad Dermatol., 2002, 47:692-700.
HHR	Guinan, E.C. et al., Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity, Blood, 1994, 84:3261-3282.
IIR	Hafler, D.A., et al., The potential of restricted T cell recognition of myelin basis protein epitopes in the therapy of multiple sclerosis, Ann. NY Acad. Sci., 1991, 636:251-265.
JJR	Hariharan et al., "In vitro and in vivo studies demonstrating the effectiveness of IDEC-114 and rituximab (Rituxan®) in therapy of B-cell lymphoma in experimental models; Confidential Report (laboratory notebook and data binder 2552, 2646, 2665, and 2671)," June 29, 2001.
KKR	Hathcock, K.S. et al., Identification of an alternative CTLA-4 ligand costimulatory for T cell activation, Science, 1993, 262:905-907.
LLR	Hollenbaugh, D., et al., The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity, The EMBO J., 1992, 11(12):4313-4321.
MMR	Janeway, C.A. et al., Signals and Signs for Lymphocyte Responses, 1994, 76:275-285.
NNR	Kahan, B.D., Immunosuppressive therapy, Curr Opin Immunol., 1992, 4:553-560.
OOR	Karpus, W.J., et al., CD4+ suppressor cells differentially affect the production of IFN-γ by effector cells of experimental autoimmune encephalomyelitis, J. Immunol., 1989, 143:3492-3497.
PPR	Laman, J., et al., The role of gp39 (CD40 ligand) in EAE and MS, Journal of Neuroimmunology, 1994, 54(1-2):175.
QQR	Lederman, S., et al., Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation (Help), J. Exp. Med., 1992, 175:1091-1101.
RRR	Lider, O., et al., Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein, J. Immunol., 1989, 142:748-752.
SSR	Linsley, P.S. et al., The role of the CD28 receptor during T cell responses to antigen, Annu Rev Immunol., 1993, 11:191-212.
TTR	Linsley, P.S. et al., T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1, Proc. Natl. Acad., 1990, 87:5031-5035.
UUR	McCafferty, J., et al., Phage antibodies: filamentous phage displaying antibody variable domains, Nature, 1990, 348:552-554.
VVR	Miller, A., et al., Antigen-driven bystander suppression after oral administration of antigens, J. Exp. Med., 1991, 174:791-798.
WW	Mokhtarian, F., et al., Adoptive transfer of myelin basic protein-sensitized T cells produces chronic relapsing demyelinating disease in mice, Nature, 1984, 309:356-358.
XXR	Morrison, S., et al., Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains, Proc. Natl. Acad. Sci. U.S.A., 1985, 81:6851-6855.
YYR	Nickoloff, B.J. et al., T lymphocytes in skin lesions of psoriasis and mycosis fungoides express B7-1: a ligand for CD28, Blood, 1994, 83:2580-2586.
ZZR	Noelle, R.J., et al., A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells, Proc. Natl. Acad. Sci. USA, 1992, 89:6550-6554.
AAA	Olsson, L., et al., Human-human monoclonal antibody-producing hybridomas: technical aspects, Meth, Enzymol., 1982, 92:3-17.
BBB	Perrin, P.J. et al., Opposing effects of CTLA4-Ig and anti-CD80 (B7-1) plus anti-CD86 (B7-2) on experimental allergic encephalomyelitis, J Neuroimmunol., 1996, 65:31-39.
CCC	Pesoa, S.A., et al., Regulation of experimental allergic encephalomyelitis. Part 5. Role of the recipient in suppressor cell induction, J. Neuroimmunol., 1984, 7:131-135.

Patent Counsel 6/18/04

	DDD	Pettinelli, C.B., et al., Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after <i>in vitro</i> activation of lymph node cells by myelin basic protein: requirement for Lyt 1 ⁺ 2 ⁺ T lymphocytes, J. Immunol., 1979, 127:1420-1423.
	EEE	Sobel, R.A., et al., Acute experimental allergic encephalomyelitis in SJL/J mice induced by a synthetic peptide of myelin proteolipid protein, J. Neuropathol. Exp. Neurol., 1990, 49(5):468-479.
	FFF	Stamenkovic, I., et al., A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas, The EMBO J., 1989, 8(5),1403-1410.
	GGG	Suvas, S. et al., Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma, J Biol Chem., 2002, 277:7766-7775.
	HHH	Takeda S., et al., Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences, Nature, 1985, 314(4):452-454.
	IIIR	Teng, N. H. et al., Construction and testing of mouse-human heteromyelomas for human monoclonal antibody production, Proc. Natl. Acad. Sci. U.S.A., 1983, 80:7308—7312.
	JJRR	Tuohy, V.K., et al., Identification of an encephalitogenic determinant of myelin proteolipid protein for SJL mice, J. Immunol., 1989, 142:1523-1527.
	KKK	Valle, A. et al., mAb 104, a new monoclonal antibody, recognizes the B7 antigen that is expressed on activated B cells and HTLV-1-transformed T cells, Immunology, 1990, 69:531-535.
	LLLR	Van der Veen, R. C. et al., The adoptive transfer of chronic relapsing experimental allergic encephalomyelitis with lymph node cells sensitized to myelin proteolipid protein, J. Neuroimmunol., 1989, 21:183-191.
	MMM	Ward, E.S., et al., Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli, Nature, 1989, 341:544-546.
NNN	Ward, P.A., et al., Blocking of adhesion molecules in vivo as anti-inflammatory therapy, Ther Immunol., 1994, 1:165-171.	
	OOO	Yi-qun, Z. et al., Differential requirements for co-stimulatory signals from B7 family members by resting versus recently activated memory T cells towards soluble recall antigens, Int Immunol., 1996, 8:37-44.
Examiner <u>Pittman, M. G. 6/12/04</u>		Date Considered:
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</p>		